




Certeogra[®] P3T Software for Abdomen Contrast Enhanced Abdominal CT

CT contrast enhanced abdominal studies are a commonly ordered procedure.¹

Bayer in Radiology's Certeogra[®] P3T Software for Abdomen is an algorithm that automates the calculation of individual IV contrast injection protocols, based on patient characteristics and contrast concentration.

There are two key factors that control the enhancement of liver parenchyma.²

1. **Body Weight** – this is the main factor




2. **Iodine concentration** of contrast media



Extensive clinical research supports weight-based contrast dosing for abdominal imaging. Three primary rationales for weight-based dosing include patient safety, consistent image quality, and potentially reduce contrast.³

Certeogra[®] P3T Software for Abdomen:

- > Automates calculation of individualized injection protocols
- > Increases consistency of individualized protocols
- > Provides multiple dosing options (weight factor, Iodine load and volume factor) for IV contrast protocol design for CT imaging of the abdominal region (i.e., liver, pancreas, kidneys) customized to radiologist preferences




Certegra® P3T Software for Abdomen

Image comparison with the same patient


- Patient weight 120 lbs.
- Contrast Concentration 350

Standard Protocol



| Piston | Flow Rate | Volume |
|-----------------|-----------|--------|
| A | 2.0 mL/s | 30 mL |
| B | 2.0 mL/s | 20 mL |
| Pause 5 minutes | | |
| A | 3.0 mL/s | 100 mL |
| B | 3.0 mL/s | 40 mL |

Certegra® P3T Abdomen



| Piston | Flow Rate | Volume |
|-----------------|-----------|--------|
| A | 1.7 mL/s | 30 mL |
| B | 1.7 mL/s | 20 mL |
| Pause 5 minutes | | |
| A | 1.7 mL/s | 57 mL |
| B | 1.7 mL/s | 40 mL |

Weight factor = 0.41g/Kg

Images provided during evaluation through the courtesy of Rhode Island Hospital. Used by Permission.

References:

- ¹ Arlington Medical Resources (AMR Data) CT procedures for the 1st half of 2014
- ² Optimal Vascular and Parenchymal Contrast Enhancement: The Current State of the Art. Dominik Fleischmann, MD, Aya Kamaya, MD Radiol Clin N Am 2009;47:13-26
- ³ Intravenous Contrast Medium Administration and Scan Timing at CT: Considerations and Approaches, Kyongtae T. Bae: Radiology 2010;256(1):32-61

Bayer reserves the right to modify the specifications and features described herein or to discontinue any product or service identified in this publication at any time without prior notice or obligation. Please contact your authorized representative from Bayer for the most current information.

Bayer, the Bayer Cross, MEDRAD, Stellant, MEDRAD Stellant, Certegra P3T, Certegra, and P3T are trademarks owned by and/or registered to Bayer in the U.S. and/or other countries. Other trademarks and company names mentioned herein are properties of their respective owners and are used herein solely for informational purposes. No relationship or endorsement should be inferred or implied.

© 2012, 2015, 2017, 2019 Bayer. This material may not be reproduced, displayed, modified or distributed without the express prior written consent of Bayer.



Bayer HealthCare LLC
 100 Bayer Boulevard
 P.O. Box 915
 Whippany, NJ 07981
 U.S.A.
 Phone: +1-412-767-2400
 +1-800-633-7231
 Fax: +1-412-767-4120



Manufacturer
 Bayer Medical Care Inc.
 1 Bayer Drive
 Indianola, PA 15051-0780
 U.S.A.
 Phone: +1-412-767-2400
 +1-800-633-7231
 Fax: +1-412-767-4120

More information on
radiologysolutions.bayer.com